1. Home
  2. ORGO vs IMUX Comparison

ORGO vs IMUX Comparison

Compare ORGO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Organogenesis Holdings Inc.

ORGO

Organogenesis Holdings Inc.

HOLD

Current Price

$1.31

Market Cap

181.4M

Sector

Health Care

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

BUY

Current Price

$7.56

Market Cap

155.8M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
ORGO
IMUX
Founded
1985
2016
Country
United States
United States
Employees
N/A
66
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
181.4M
155.8M
IPO Year
2016
2013

Fundamental Metrics

Financial Performance
Metric
ORGO
IMUX
Price
$1.31
$7.56
Analyst Decision
Hold
Strong Buy
Analyst Count
2
12
Target Price
$2.00
★ $43.09
AVG Volume (30 Days)
★ 605.5K
385.8K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1600.00
38.00
EPS
★ N/A
N/A
Revenue
★ $564,169,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$37.55
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 17.04
N/A
52 Week Low
$1.28
$0.51
52 Week High
$7.08
$17.43

Technical Indicators

Market Signals
Indicator
ORGO
IMUX
Relative Strength Index (RSI) 32.51 23.18
Support Level N/A $0.78
Resistance Level $2.69 $15.82
Average True Range (ATR) 0.06 0.65
MACD 0.01 -0.11
Stochastic Oscillator 13.64 3.43

Price Performance

Historical Comparison
ORGO
IMUX

About ORGO Organogenesis Holdings Inc.

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: